Dermatologic Manifestations of Merkel Cell Carcinoma
- Author: Christopher R Shea, MD; Chief Editor: Dirk M Elston, MD more...
Background
Merkel cell carcinoma (MCC) is a rare, aggressive, primary skin cancer exhibiting neuroendocrine differentiation. Several synonyms exist; however, the term Merkel cell carcinoma is still most commonly used in view of the many similarities of the constituent tumor cell to the normal Merkel cell of the skin. In 1875, Friedrich Sigmund Merkel described tastzellen (touch cells) in the skin of the snouts of moles and pigs and proposed that they had a mechanoreceptor function.
In human development, Merkel cells appear by the eighth gestational week, possibly being derived from a primitive epidermal stem cell. Merkel cells are present in high numbers on the lip, hard palate, palms, finger pads, proximal nail folds, and dorsa of the feet. Merkel cells have a predilection for perifollicular areas in the skin; confirmed reports exist of Merkel cells free in the dermis, but they are most easily identified in the basal layer of the epidermis. Functions proposed for normal Merkel cells in skin include induction or stimulation of perifollicular or dermal nerve plexuses via a direct complex, stimulation of keratinocyte proliferation and maintenance of their differentiation, histogenesis of the nail, and release of various bioactive substances to the dermis. Studies documenting marked cyclical changes in the number of dendritic-type Merkel cells in rat skin suggest a secretory function related to the hair cycle.[1]
Also see Merkel Cell Tumors of the Head and Neck and Skin Malignancies, Merkel Cell Carcinoma and Rare Appendageal Tumors.
Pathophysiology
The histogenesis of Merkel cell carcinoma is controversial. Possible cells of origin include the epidermal Merkel cell, a dermal Merkel cell equivalent, a neural-crest–derived cell of the amine precursor uptake and decarboxylation (APUD) system, and a residual epidermal stem cell.
Cytogenetic abnormalities are present in 30-47% of Merkel cell carcinomas. The most frequent change is loss of heterozygosity due to translocations or deletions of chromosome 1; specifically, 2 distinct regions in the most distal band 1p36 on the short arm of chromosome 1 are implicated in Merkel cell carcinoma. Similar abnormalities near this site occur in several neurocristic tumors, including melanoma, neuroblastoma, and pheochromocytoma. Other abnormalities described in Merkel cell carcinoma include losses at chromosomes 3, 13, and 22 and partial trisomy of chromosomes 1, 11, 18, and X.[2, 3, 4, 5, 6] Unlike neuroendocrine (small cell) carcinoma of the lung, gene amplifications are rare in cutaneous Merkel cell carcinoma.
Epidemiology
Frequency
United States
Merkel cell carcinoma is a rare tumor, accounting for less than 1% of cutaneous malignancies. In Rochester, Minnesota, the annual incidence of Merkel cell carcinoma was reported to be 0.2 case per 100,000 residents. In a study of 1,124 cases of Merkel cell carcinoma identified in the Surveillance, Epidemiology, and End Results (SEER) database, the incidence increased over a 15-year period (from 0.15 case per 100,000 in 1986 to 0.44 case per 100,000 in 2001).[7]
Mortality/Morbidity
Overall, the 2-year survival rate is 50-70%.
Race
Whites have a 20-fold increased age-adjusted relative risk of developing Merkel cell carcinoma compared with blacks.
Sex
The incidence reported in most studies is approximately equal for males and females, although some authors report an elevated female-to-male ratio of up to 4:1. Survival is greater in women.[8]
Age
The mean patient age at diagnosis is about 75 years[9] ; only 5% of cases occur before age 50 years.
Nakafusa J, Narisawa Y, Shinogi T, et al. Changes in the number of Merkel cells with the hair cycle in hair discs on rat back skin. Br J Dermatol. Nov 2006;155(5):883-9. [Medline].
Leonard JH, Hayard N. Loss of heterozygosity of chromosome 13 in Merkel cell carcinoma. Genes Chromosomes Cancer. Sep 1997;20(1):93-7. [Medline].
Leonard JH, Williams G, Walters MK, Nancarrow DJ, Rabbitts PH. Deletion mapping of the short arm of chromosome 3 in Merkel cell carcinoma. Genes Chromosomes Cancer. Feb 1996;15(2):102-7. [Medline].
Van Gele M, Speleman F, Vandesompele J, Van Roy N, Leonard JH. Characteristic pattern of chromosomal gains and losses in Merkel cell carcinoma detected by comparative genomic hybridization. Cancer Res. Apr 1 1998;58(7):1503-8. [Medline].
Van Gele M, Van Roy N, Ronan SG, et al. Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas. Genes Chromosomes Cancer. Sep 1998;23(1):67-71. [Medline].
Vortmeyer AO, Merino MJ, Böni R, Liotta LA, Cavazzana A, Zhuang Z. Genetic changes associated with primary Merkel cell carcinoma. Am J Clin Pathol. May 1998;109(5):565-70. [Medline].
Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. Jan 1 2005;89(1):1-4. [Medline].
Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope. Mar 1992;102(3):244-9. [Medline].
Mott RT, Smoller BR, Morgan MB. Merkel cell carcinoma: a clinicopathologic study with prognostic implications. J Cutan Pathol. Mar 2004;31(3):217-23. [Medline].
Gipponi M. Clinical applications of sentinel lymph-node biopsy for the staging and treatment of solid neoplasms. Minerva Chir. Aug 2005;60(4):217-33. [Medline].
Gupta SG, Wang LC, Penas PF, Gellenthin M, Lee SJ, Nghiem P. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. Jun 2006;142(6):685-90. [Medline].
Schmalbach CE, Lowe L, Teknos TN, Johnson TM, Bradford CR. Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. Arch Otolaryngol Head Neck Surg. Jul 2005;131(7):610-4. [Medline].
Wasserberg N, Schachter J, Fenig E, Feinmesser M, Gutman H. Applicability of the sentinel node technique to Merkel cell carcinoma. Dermatol Surg. Feb 2000;26(2):138-41. [Medline].
Gooptu C, Woollons A, Ross J, et al. Merkel cell carcinoma arising after therapeutic immunosuppression. Br J Dermatol. Oct 1997;137(4):637-41. [Medline].
Shaw M, Warren S, Groben P, Gulley ML. No evidence of Epstein-Barr virus association with Merkel cell carcinoma. J Cutan Pathol. Sep 2006;33(9):624-8. [Medline].
Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. Feb 22 2008;319(5866):1096-100. [Medline].
Toker C. Trabecular carcinoma of the skin. Arch Dermatol. Jan 1972;105(1):107-10. [Medline].
Hashimoto K, Lee MW, D'Annunzio DR, Balle MR, Narisawa Y. Pagetoid Merkel cell carcinoma: epidermal origin of the tumor. J Cutan Pathol. Nov 1998;25(10):572-9. [Medline].
Gould E, Albores-Saavedra J, Dubner B, Smith W, Payne CM. Eccrine and squamous differentiation in Merkel cell carcinoma. An immunohistochemical study. Am J Surg Pathol. Oct 1988;12(10):768-72. [Medline].
Iacocca MV, Abernethy JL, Stefanato CM, Allan AE, Bhawan J. Mixed Merkel cell carcinoma and squamous cell carcinoma of the skin. J Am Acad Dermatol. Nov 1998;39(5 Pt 2):882-7. [Medline].
Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. Feb 1999;8(2):153-8. [Medline].
Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol. May 1995;8(4):384-8. [Medline].
Shah IA, Netto D, Schlageter MO, Muth C, Fox I, Manne RK. Neurofilament immunoreactivity in Merkel-cell tumors: a differentiating feature from small-cell carcinoma. Mod Pathol. Jan 1993;6(1):3-9. [Medline].
Collins BT, Elmberger PG, Tani EM, Bjornhagen V, Ramos RR. Fine-needle aspiration of Merkel cell carcinoma of the skin with cytomorphology and immunocytochemical correlation. Diagn Cytopathol. Apr 1998;18(4):251-7. [Medline].
Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. Nov 2010;63(5):751-61. [Medline]. [Full Text].
Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer. Jun 15 1999;85(12):2589-95. [Medline].
Decker RH, Wilson LD. Role of radiotherapy in the management of merkel cell carcinoma of the skin. J Natl Compr Canc Netw. Aug 2006;4(7):713-8. [Medline].
Meeuwissen JA, Bourne RG, Kearsley JH. The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys. Jan 15 1995;31(2):325-31. [Medline].
Senchenkov A, Barnes SA, Moran SL. Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. J Surg Oncol. Mar 1 2007;95(3):229-34. [Medline].
Veness MJ, Perera L, McCourt J, et al. Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ J Surg. May 2005;75(5):275-81. [Medline].
O'Connor WJ, Roenigk RK, Brodland DG. Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg. Oct 1997;23(10):929-33. [Medline].
Leong SP. Selective sentinel lymphadenectomy for malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma. Cancer Treat Res. 2005;127:39-76. [Medline].
Kokoska ER, Kokoska MS, Collins BT, Stapleton DR, Wade TP. Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg. Dec 1997;174(6):688-93. [Medline].
Takenaka H, Kishimoto S, Shibagaki R, Nagata M, Yasuno H. Merkel cell carcinoma with partial spontaneous regression: an immunohistochemical, ultrastructural, and TUNEL labeling study. Am J Dermatopathol. Dec 1997;19(6):614-8. [Medline].
Ng L, Beer TW, Murray K. Vascular density has prognostic value in Merkel cell carcinoma. Am J Dermatopathol. Oct 2008;30(5):442-5. [Medline].
Amo-Takyi BK, Tietze L, Tory K, et al. Diagnostic relevance of chromosomal in-situ hybridization in Merkel cell carcinoma: targeted interphase cytogenetic tumour analyses. Histopathology. Feb 1999;34(2):163-9. [Medline].
Haag ML, Glass LF, Fenske NA. Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg. Aug 1995;21(8):669-83. [Medline].
Miettinen M, Lasota J. Cutaneous lymphoma-simulating Merkel cell carcinoma-molecular genetic demonstration of a clonal disease with divergent immunophenotypes. Mod Pathol. Sep 1995;8(7):769-74. [Medline].
Moll I, Moll R. Early development of human Merkel cells. Exp Dermatol. Nov 1992;1(4):180-4. [Medline].
Pilotti S, Rilke F, Bartoli C, Grisotti A. Clinicopathologic correlations of cutaneous neuroendocrine Merkel cell carcinoma. J Clin Oncol. Dec 1988;6(12):1863-73. [Medline].
Plaza JA, Suster S. The Toker tumor: spectrum of morphologic features in primary neuroendocrine carcinomas of the skin (Merkel cell carcinoma). Ann Diagn Pathol. Dec 2006;10(6):376-85. [Medline].
Ratner D, Nelson BR, Brown MD, Johnson TM. Merkel cell carcinoma. J Am Acad Dermatol. Aug 1993;29(2 Pt 1):143-56. [Medline].
Savage P, Constenla D, Fisher C, Thomas JM, Gore ME. The natural history and management of Merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital. Clin Oncol (R Coll Radiol). 1997;9(3):164-7. [Medline].
Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol. Nov 1997;37(5 Pt 1):734-9. [Medline].
Smith DE, Bielamowicz S, Kagan AR, Anderson PJ, Peddada AV. Cutaneous neuroendocrine (Merkel cell) carcinoma. A report of 35 cases. Am J Clin Oncol. Jun 1995;18(3):199-203. [Medline].
Suárez C, Rodrigo JP, Ferlito A, Devaney KO, Rinaldo A. Merkel cell carcinoma of the head and neck. Oral Oncol. Sep 2004;40(8):773-9. [Medline].
Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. Jun 2000;18(12):2493-9. [Medline].
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ |
| T1 | Tumor 2 cm or less in greatest dimension |
| T2 | Tumor >2 cm but not >5 cm in greatest dimension |
| T3 | Tumor >5 cm in greatest dimension |
| T4 | Tumor invades deep extradermal structures (ie, cartilage, skeletal muscle, bone) |
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Regional lymph metastasis |
| MX | Distant metastasis cannot be assessed |
| M0 | No distant metastasis |
| M1 | Distant metastasis |
| Stage 0 | Tis | N0 | M0 |
| Stage I | T1 | N0 | M0 |
| Stage II | T2 | N0 | M0 |
| (or) | T3 | N0 | M0 |
| Stage III | T4 | N0 | M0 |
| (or) | Any T | N1 | M0 |
| Stage IV | Any T | Any N | M1 |

